0000000000653155

AUTHOR

Joseph Kerger

showing 3 related works from this author

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

2016

0301 basic medicineOncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtybusiness.industryMelanomaHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinePimasertibIn patientDacarbazine - DTICOpen labelbusinessAnnals of Oncology
researchProduct

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

2020

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg

Cancer ResearchGastroenterologypimasertiblaw.invention0302 clinical medicineRandomized controlled triallawClinical endpoint030212 general & internal medicineMalignant melanomaHazard ratioProgression-free survivalSciences bio-médicales et agricoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthDacarbazineOncology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030220 oncology & carcinogenesismedicine.symptomPimasertibmedicine.drugQuality of lifemedicine.medical_specialtyNauseaDacarbazinemalignant melanomadacarbazine[SDV.CAN]Life Sciences [q-bio]/CancerN-(2 3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNeutropeniaN-(23-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamidelcsh:RC254-282Article03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicinemedicineProgression-free survivalAdverse effectbusiness.industry[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.diseaseadverse eventsCancérologiequality of lifeAdverse events[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologybusinessprogression-free survival[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

2017

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentMedizinLeucovorinProspective cohort study[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXOrganoplatinum Compounds/therapeutic useAntineoplastic Combined Chemotherapy ProtocolstudyLymphocytesProspective StudiesProspective cohort studyLeucovorin/therapeutic useMiddle AgedPrognosis3. Good healthColorectal carcinomaOncologyFluorouracil030220 oncology & carcinogenesisPredictive value of testsColonic NeoplasmsBiomarker (medicine)Lymphocytes/pathologyFemaleFluorouracilAdjuvantmedicine.drugAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerFluorouracil/therapeutic useBiomarkers Tumor/analysis03 medical and health sciencesLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarker; Colorectal carcinoma; Immune response; Prospective cohort study; Oncology; Cancer ResearchInternal medicinemedicineBiomarkers TumorHumansImmune responseSurvival analysisAgedbusiness.industryBiomarkermedicine.diseaseSurvival AnalysisSurgery030104 developmental biologyProspective cohort&nbspMultivariate AnalysisColonic Neoplasms/diagnosisAntineoplastic Combined Chemotherapy Protocols/therapeutic usebusiness
researchProduct